Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILT-CD vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension,Chronic stable angina,Variant angina,Atrial fibrillation or atrial flutter (rate control),Paroxysmal supraventricular tachycardia
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal elimination half-life 7-10 hours; clinically relevant in hepatic impairment (prolonged to 14-20 hours) and in elderly
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Hepatic via CYP3A4; undergoes deacetylation and N-demethylation.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal 2-4% unchanged; extensive hepatic metabolism; 60-70% fecal, 30-40% renal as metabolites
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
85-90% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein)
92-98% bound primarily to albumin.
3-5 L/kg; large Vd indicates extensive tissue binding, with highest concentrations in liver, lung, and spleen
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral immediate-release: 40-60% (first-pass effect); oral sustained-release: 30-50%; IV: 100%
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No dosage adjustment required for mild-moderate renal impairment; use caution and consider dose reduction in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated or use with extreme caution, reduce dose by at least 50%.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not FDA-approved for pediatric use; off-label dosing for hypertension: extended-release initial 2.5-5 mg/kg/day PO once daily, max 10 mg/kg/day up to 360 mg daily; for supraventricular tachycardia: IV bolus 0.1-0.3 mg/kg over 2 min, may repeat after 30 min, max 10 mg/dose.
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at lower end of dosing range (e.g., 120 mg PO once daily for hypertension); titrate slowly; monitor for hypotension, bradycardia, and constipation; consider reduced initial dose due to altered pharmacokinetics.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None.
No FDA black box warning.
May cause bradycardia, heart block, or heart failure exacerbation,Use caution in patients with impaired left ventricular function,May cause hypotension, especially in patients with aortic stenosis,May increase digoxin and cyclosporine levels,Abrupt withdrawal may exacerbate angina,Hepatic impairment may require dose adjustment,Avoid use in patients with sick sinus syndrome or second/third-degree AV block without pacemaker
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Known hypersensitivity to diltiazem,Concomitant use with dantrolene (risk of ventricular fibrillation),Concurrent use with ivabradine
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase diltiazem levels, raising risk of toxicity. High-fat meals may increase absorption; take with food to reduce gastrointestinal upset. Alcohol may enhance hypotension and dizziness; limit consumption.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
DILT-CD is a formulation of diltiazem, a calcium channel blocker. In animal studies, diltiazem has been associated with fetal skeletal abnormalities and reduced fetal weight at high doses. Human data are limited; however, diltiazem is generally avoided in the first trimester due to potential teratogenic effects. In the second and third trimesters, use is cautioned due to risks of maternal hypotension and possible fetal hypoxia. Diltiazem crosses the placenta and may cause fetal bradycardia.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Diltiazem is excreted into breast milk in small amounts; the estimated infant dose is approximately 1% of the maternal weight-adjusted dose. The milk-to-plasma ratio (M/P) is reported as 0.5-1.0. Caution is advised due to potential cardiovascular effects in the nursing infant, though limited data suggest low risk. Monitor infant for bradycardia and hypotension.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pregnancy may increase diltiazem clearance due to expanded plasma volume and enhanced hepatic metabolism. Dose adjustments may be needed to maintain efficacy; however, specific pharmacokinetic studies for DILT-CD are lacking. Generally, use the lowest effective dose and monitor clinical response. Titrate based on maternal blood pressure and heart rate.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
DILT-CD is a calcium channel blocker (non-dihydropyridine) used for hypertension and angina. It has negative chronotropic and dromotropic effects; avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. Monitor heart rate and PR interval. May increase digoxin levels; co-administration requires dose adjustment. Contraindicated with IV beta-blockers due to risk of bradycardia and heart failure.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take exactly as prescribed; do not crush or chew extended-release capsules.,May cause dizziness or lightheadedness; avoid driving until you know how this medication affects you.,Report slow heartbeat, shortness of breath, or swelling in your ankles or feet.,Limit alcohol intake as it may increase side effects.,Avoid grapefruit and grapefruit juice as they can increase drug levels and side effects.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILT-CD vs ADALAT CC, answered by our medical review team.
DILT-CD is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILT-CD and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILT-CD is: 180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILT-CD and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILT-CD is classified as Category C. DILT-CD is a formulation of diltiazem, a calcium channel blocker. In animal studies, diltiazem has been associated with fetal skeletal abnormalities and reduced fetal weight at hig. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.